Multiple myeloma (MM) is a malignant disorder characterized by neoplastic growth of plasma cells in the bone marrow (1). It is suggested to arise by clonal expansion of plasma cells leading to a condition known as monoclonal gammopathy of undetermined significance (MGUS), which may evolve to smouldering myeloma and finally to symptomatic myeloma (2). Features of symptomatic myeloma are, apart from the production of a clonal protein detected in the serum or urine in most of the cases, the presence of end-organ damage, appearing as anaemia, hypercalcemia, renal impairment, and bone disease (1). This article is protected by copyright. All rights reserved.